2024年11月4日 · 针对通用型car-t的关键挑战---hvgr，科济药业发展了thank-ucar技术，利用nkg2a car与b2m敲除的组合，同时减免宿主t细胞和nk细胞对ucar t细胞的杀伤，进而促使ucar t的扩增，其临床疗效值得期待。

2016年12月2日 · In this study, we developed protocols to efficiently generate CAR-T cells with two (TRAC and B2M) or three genes (TRAC, B2M, and PD-1) disrupted and tested their anti-tumor functions in vitro...

2023年2月22日 · 为了克服 gvhd 的发生和对 car-t 细胞的强烈排斥，crispr/cas9 介导的内源性 αβ t 细胞受体 (tcr) 消融在临床前研究中取得了显着成功。 过继转移的供体淋巴细胞上的内源性αβTCR可以识别人白细胞抗原（HLA）错配受体中的同种抗原，从而导致GVHD；另一方面，在供 …

2023年4月18日 · 该研究通过crispr-cas9基因编辑敲除了t细胞的trac、b2m和ciita基因，从而构建出了人类低免疫（hip）t细胞。然后，使用慢病毒载体让这些hip t细胞过表达cd47和cd19 car，构建出了异基因hip cd19 car-t细胞。

2021年10月1日 · Increasing evidence has indicated that B2M gene alterations in tumor cells may lower the efficacy of T-cell based immunotherapies by hampering MHC class I-mediated tumor antigen presentation and avoiding T cell recognition. In this review, we first introduce the biological functions of B2M in cancer and non-cancer.

2025年2月11日 · t细胞受体（tcr）：tcr是t细胞特异性识别抗原的关键分子，去除tcr可降低异基因t细胞的免疫排斥反应。 β2微球蛋白（b2m）：b2m是mhc-i复合物的组成部分，其缺失可阻止t细胞被宿主免疫系统识别。

Endogenous TCRA and β-2 microglobulin(B2M) genes are disrupted simultaneously by applying CRISPR RNA electroporation to manufacture UCAR-T cells, which are both TCR and MHC-I negative, aiming to evade rejection and deliver antileukemic effects without GVHD, but the results of these studies are still unpublished.

Here, we generated HLA class I, HLA class II, and T-cell receptor (TCR) triple-knockout (tKO) T cells by simultaneous knockout of the B2M, CIITA, and TRAC genes through Cas9/sgRNA ribonucleoprotein electroporation. Although HLA-deficient T cells were targeted by natural killer cells, they persisted better than HLA-sufficient T cells in the ...

2025年3月7日 · At the targeted B2M intron, average knock-in efficiency ranged from ~10% to 50% depending on the gRNA used, and the percentage of B2M (HLA-A/B/C) − cells that were knock-in positive relative to ...

2019年5月15日 · 本发明人经过广泛而深入的研究，筛选了大量的靶向tcr的α链、β1链、β2链和b2m基因位点的sgrna，意外地发现一种用于制备通用型car-t细胞的试剂，靶向tcr和/或b2m的sgrna或用于表达所述sgrna的表达载体。